Skip to main content
F

Firasah

Inactive

Firasah provides a platform that aggregates cancer patients' genomic data and matches them with suitable clinical trials, targeted therapies, and compassionate‑use programs across Saudi Arabia and the MENA region. The service streamlines referrals between hospitals, trial sites, and biopharma partners, enabling oncology clinics to enroll patients more efficiently and expand precision‑medicine options.

Riyadh, Saudi Arabia10+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Patients with cancer in Saudi Arabia and the broader MENA region often lack timely access to comprehensive genomic profiling, targeted clinical trials, and compassionate‑use therapies, limiting personalized treatment options and affecting outcomes.

Solution

Firasah operates a proprietary platform that aggregates patients’ genomic data and matches it to the most appropriate clinical trials and targeted therapies available in the region. The platform streamlines referral pathways between hospitals, biopharma partners, and trial sponsors, enabling clinicians to identify and enroll eligible patients more efficiently. By facilitating compassionate‑use access, Firasah expands treatment options beyond standard care, aiming to improve survival and quality of life. The company also collaborates with regional healthcare leaders to build a sustainable precision‑oncology ecosystem that supports ongoing research and drug development.

Target Audience

Primary customers are oncology clinics, hospitals, and cancer treatment centers in Saudi Arabia and the MENA region seeking to offer their patients access to precision‑medicine options and clinical trial participation.

Features

  • Centralized database that integrates patients’ genomic profiles with a curated catalog of regional and international oncology trials
  • Automated matching algorithm that recommends the best‑fit targeted therapies and compassionate‑use programs based on molecular alterations
  • End‑to‑end referral workflow linking hospitals, trial sites, and biopharma sponsors to accelerate patient enrollment
  • Secure, HIPAA‑compliant data handling and encryption to protect patient privacy
  • Partnership network with leading healthcare institutions and pharmaceutical companies to expand trial availability in the MENA region
This profile is AI-generated and may contain inaccuracies.